BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, ...

Stay updated on the latest stock market trends and company earnings. Discover the impact of market gains and profit reports ...

U.S. stock futures are edging mostly higher as market participants focus on tech stocks and corporate earnings; Honeywell announces a split of its automation, aerospace, and advan ...

In this article, we are going to take a look at where QUALCOMM Incorporated (NASDAQ:QCOM) stands against other best socially responsible stocks to buy according to hedge funds. Socially responsible ...

In this article, we are going to take a look at where QUALCOMM Incorporated (NASDAQ:QCOM) stands against the other dividend stocks. Dividend stocks, while popular among investors, have been ...

Madison Investments highlighted QCOM in its Q3 2024 investor letter. Here is what the firm has to say: “Alphabet Inc., Eli Lilly and Company, QUALCOMM Incorporated (NASDAQ:QCOM), Microsoft ...

In this article, we are going to take a look at where QUALCOMM Incorporated (NASDAQ:QCOM) stands against the other semiconductor stocks. More than two years have passed since the proliferation of the ...